γ-Carboxyglutamic acid content of hepatocellular carcinoma-associated des-γ-carboxy prothrombin

Serum des-gamma-carboxy prothrombin (DCP) is a useful marker for the diagnosis of hepatocellular carcinoma (HCC), but the exact mechanism of its synthesis and its structural properties in liver diseases are unknown. DCP is measured by the monoclonal antibody MU-3. The purpose of this study was to examine the epitope of MU-3 and to characterize the differences in DCP between HCC and benign liver diseases. The epitope of MU-3 was examined by ELISA using prothrombin Gla domain polypeptides and was determined to be amino acid residues 17-27 of the prothrombin Gla domain, which has four gamma-carboxyglutamic acid residues (Gla) at positions 19, 20, 25 and 26. Peptides having a glutamic acid residue (Glu) at these positions reacted strongly to MU-3 but lost reactivity when Glu 19 or 20 was changed to Gla. In the order of gamma-carboxylation, MU-3 reacted strongly to DCP containing 0-1 Gla, weakly to 2-4 Gla and not at all to DCP containing more than five Gla. After adsorbing normal prothrombin with barium carbonate, DCP reaction to MU-3 was measured by determining the amount of DCP that was adsorbed by MU-3-coated beads. The proportion of DCP reacting to MU-3 in HCC was 41.0-76.8%, whereas in patients with benign liver diseases, only 0-42.1% reacted to MU-3. These results indicate that DCP variants preferentially synthesized in HCC have less than four Gla, which are restricted to positions 16, 25, 26 and 29, whereas DCP variants in benign liver diseases have more than five Gla.

[1]  T. Suzuki,et al.  Studies on the activation of bovine prothrombin. Isolation and characterization of the fragments released from the prothrombin by activated factor X. , 1974, Journal of biochemistry.

[2]  H. Liebman.  Isolation and characterization of a hepatoma-associated abnormal (des-gamma-carboxy)prothrombin. , 1989, Cancer research.

[3]  B. Furie,et al.  Distribution of gamma-carboxyglutamic acid residues in partially carboxylated human prothrombins. , 1986, The Journal of biological chemistry.

[4]  M. Omata,et al.  Nucleotide sequence of prothrombin gene in abnormal prothrombin‐producing hepatocellular carcinoma cell lines , 1992, Cancer.

[5]  H. Asakura,et al.  The usefulness of determining des‐γ‐carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma , 1998, Cancer.

[6]  M. Ono,et al.  Increase of Serum Des-gamma-Carboxy Prothrombin in Alcoholic Liver Disease Without Hepatocellular Carcinoma. , 1999, Alcoholism, clinical and experimental research.

[7]  B. Furie,et al.  Prothrombin requires two sequential metal-dependent conformational transitions to bind phospholipid. Conformation-specific antibodies directed against the phospholipid-binding site on prothrombin. , 1986, The Journal of biological chemistry.

[8]  K. Chayama,et al.  Serum des‐gamma‐carboxyprothrombin concentration determined by the avidin‐biotin complex method in small hepatocellular carcinomas , 1994, Cancer.

[9]  Shou-Dong Lee,et al.  Des-γ-Carboxy (Abnormal) Prothrombin as a Serum Marker of Primary Hepatocellular Carcinoma , 1984 .

[10]  D. Stafford,et al.  A Missense Mutation in γ-Glutamyl Carboxylase Gene Causes Combined Deficiency of All Vitamin K-Dependent Blood Coagulation Factors , 1998 .

[11]  R. Brebant,et al.  Production of a new monoclonal antibody specific to human des-gamma-carboxyprothrombin in the presence of calcium ions. Application to the development of a sensitive ELISA-test. , 1995, Journal of immunoassay.

[12]  J. Belghiti,et al.  Mechanism of the abnormal vitamin k‐dependent γ‐carboxylation process in human hepatocellular carcinomas , 1994 .

[13]  B. Furie,et al.  The importance of specific gamma-carboxyglutamic acid residues in prothrombin. Evaluation by site-specific mutagenesis. , 1993, The Journal of biological chemistry.

[14]  K. Katayama,et al.  An improved method for the determination of γ-carboxyglutamic acid in proteins, bone, and urine , 1983 .

[15]  B. Burr,et al.  Slab gel system for the resolution of oligopeptides below molecular weight of 10,000. , 1983, Methods in Enzymology.

[16]  Inda,et al.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.

[17]  J. Amiral,et al.  Specific measurement of hypocarboxylated prothrombin in plasma or serum and application to the diagnosis of hepatocellular carcinoma. , 1996, The Journal of laboratory and clinical medicine.

[18]  K. Honjo,et al.  Process of carboxylation of glutamic acid residues in the gla domain of human des-gamma-carboxyprothrombin. , 1999, Clinica chimica acta; international journal of clinical chemistry.

[19]  S. Moore,et al.  Automatic recording apparatus for use in the chromatography of amino acids. , 1958, Federation proceedings.

[20]  R. Lamerz,et al.  Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases. , 1999, Anticancer research.

[21]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[22]  B. Furie,et al.  Acquired vitamin K-dependent carboxylation deficiency in liver disease. , 1981, The New England journal of medicine.

[23]  S. Bajaj,et al.  Decarboxylation of gamma-carboxyglutamic acid residues in human prothrombin. Stoichiometry of calcium binding to gamma-carboxyglutamic acid in prothrombin. , 1982, The Journal of biological chemistry.

[24]  A. Tulinsky,et al.  Structure of Ca2+ prothrombin fragment 1 including the conformation of the Gla domain. , 1989, Biochemistry.

[25]  F. Endo,et al.  Detection of vitamin K deficiency by use of an enzyme-linked immunosorbent assay for circulating abnormal prothrombin. , 1985, Pediatric research.

[26]  A. Nakao,et al.  Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma. , 1994, The American journal of gastroenterology.

[27]  D. Earnest,et al.  Prothrombin antigen and coagulant activity in patients with liver disease. , 1982, JAMA.

[28]  R. MacGillivray,et al.  Characterization of the complementary deoxyribonucleic acid and gene coding for human prothrombin. , 1983, Biochemistry.

[29]  M. Esnouf.  Vitamin K Metabolism and Vitamin K Dependent Proteins , 1980 .

[30]  Monoclonal antibodies against human abnormal (des-gamma-carboxy)prothrombin specific for the calcium-free conformer of prothrombin. , 1984, The Journal of biological chemistry.

[31]  K. Kurachi,et al.  Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). , 1985, Biochemistry.

[32]  J. Suttie,et al.  Location of gamma-carboxyglutamyl residues in partially carboxylated prothrombin preparations. , 1988, Biochemistry.

[33]  K. Tanikawa,et al.  A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. , 2000, Oncology reports.

[34]  T. Yokoo,et al.  Measurement of serum levels of des‐γ‐carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity , 1999, Cancer.

[35]  A. Shirahata,et al.  Vitamin K Contents in Liver Tissue of Hepatocellular Carcinoma Patients , 2000, Japanese journal of cancer research : Gann.

[36]  H. El‐Serag,et al.  Rising incidence of hepatocellular carcinoma in the United States. , 1999, The New England journal of medicine.

[37]  K. Fujikawa,et al.  Complete amino acid sequence of the light chain of human blood coagulation factor X: evidence for identification of residue 63 as beta-hydroxyaspartic acid. , 1983, Biochemistry.

[38]  F. Endo,et al.  EFFECT OF VITAMIN K ADMINISTRATION ON ACARBOXY PROTHROMBIN (PIVKA-II) LEVELS IN NEWBORNS , 1985, The Lancet.

[39]  D. Monard,et al.  cDNA sequence of rat prothrombin. , 1990, Nucleic acids research.

[40]  H. Obata,et al.  Levels of vitamin K, immunoreactive prothrombin, des‐γ‐carboxy prothrombin and γ‐glutamyl carboxylase activity in hepatocellular carcinoma tissue , 1995 .

[41]  Y. Sakata,et al.  The acquired vitamin K‐dependent γ‐carboxylation deficiency in hepatocellular carcinoma involves not only prothrombin, but also protein C , 1988, Hepatology.

[42]  J. Miletich,et al.  The synthesis of sulfated dextran beads for isolation of human plasma coagulation factors II, IX, and X. , 1980, Analytical biochemistry.

[43]  B. Furie,et al.  Immunoassays of human prothrombin species which correlate with functional coagulant activities. , 1983, The Journal of laboratory and clinical medicine.

[44]  T. Kashiwagi,et al.  Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma. , 1999, Hepato-gastroenterology.

[45]  K. Watanabe,et al.  Chemical modification of gamma-carboxyglutamic acid residues in prothrombin elicits a conformation similar to that of abnormal (des-gamma-carboxy)prothrombin. , 1990, Journal of biochemistry.

[46]  Y. Shiratori,et al.  Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des‐γ‐carboxy prothrombin and low serum α‐fetoprotein , 2000 .

[47]  K. Sagara,et al.  Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma. , 1986, Hepato-gastroenterology.

[48]  H. Ohta,et al.  Measurement of immunoreactive prothrombin, des-gamma-carboxy prothrombin, and vitamin K in human liver tissues: overproduction of immunoreactive prothrombin in hepatocellular carcinoma. , 1990, The American journal of gastroenterology.

[49]  C. Jenkin,et al.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. , 1978, Immunochemistry.